Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/24
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/24
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash TransactionGlobeNewsWire • 06/27/24
Coherus Management to Present at the 2024 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/30/24
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/23/24
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHAGlobeNewsWire • 05/23/24
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian CancerGlobeNewsWire • 05/08/24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/24/24
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual MeetingGlobeNewsWire • 04/08/24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateGlobeNewsWire • 03/13/24